Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Postmenopausal Metastatic Breast Cancer

Postmenopausal Metastatic Breast Cancer Endocrine therapy and chemotherapy play important roles in the management of postmenopausal women with metastatic breast cancer. This paper specifically reviews the indications and options for first-line treatment of metastatic breast cancer and recent advances are highlighted, with particular attention to randomized, controlled, phase III clinical trials. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png American Journal of Cancer Springer Journals

Postmenopausal Metastatic Breast Cancer

Download PDF
15 pages

Loading next page...
 
/lp/springer-journals/postmenopausal-metastatic-breast-cancer-4Nnny1KDcj
Publisher
Springer Journals
Copyright
Copyright © 2003 by Adis Data Information BV
Subject
Pharmacy; Pharmacy
ISSN
1175-6357
DOI
10.2165/00024669-200302020-00003
Publisher site
See Article on Publisher Site

Abstract

Endocrine therapy and chemotherapy play important roles in the management of postmenopausal women with metastatic breast cancer. This paper specifically reviews the indications and options for first-line treatment of metastatic breast cancer and recent advances are highlighted, with particular attention to randomized, controlled, phase III clinical trials.

Journal

American Journal of Cancer – Springer Journals

Published: Aug 10, 2012

References

  • Mortality statistics: review of the Register General on deaths by sex and age, England and Wales
  • Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer
    Greenberg, P.; Hortobagyi, G.; Smith, T.
  • Polychemotherapy for early breast cancer: an overview of the randomised trials
  • Tamoxifen for early breast cancer: an overview of the randomised trials
  • Treatment of relapse of breast cancer after adjuvant systemic therapy
    Rubens, R.; Bajetta, E.; Bonneterre, J.
  • Measurement of steroid hormone receptors in breast cancer patients on tamoxifen
    Encarnacion, C.; Ciocca, D.; McGuire, W.
  • Changes in estrogen receptor, progesterone receptor, and pS2 expression in tamoxifen-resistant human breast cancer
    Johnston, S.R.; Saccani Totti, G.; Smith, I.E.
  • Textbook of medical oncology
    Goldhirsch, A.
  • Acquired tamoxifen resistance in human breast cancer: potential mechanisms and clinical implications
    Johnston, S.R.D.
  • Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer
    Howell, A.; DeFriend, D.; Robertson, J.
  • Fuivestrant is as effective as anastrozoie in post-menopausal women with advanced breast cancerprogressing after prior treatment
    Howell, A.; Robertson, J.R.F.; Albano, J.
  • Double-blind randomized trial comparing the efficacy and tolerability of fuivestrant versus anastrozole in post-menopausal women with advanced breast cancer progressing after prior endocrine therapy
    Osbourne, C.K.; Pippen, J.; Jones, S.E.
  • Endocrine manipulation in advanced breast cancer: recent advances with SERM therapies
    Johnston, S.
  • Raloxifene HCL, a new endocrine agent, is active in estrogen receptor positive (ER+) metastatic breast cancer
    Gradishar, W.; Giusman, J.; Vogel, C.
  • The effect of raloxifene on risk of breast cancer in posmtenopausal women: results from the multiple outcomes of raloxifene evaluation (MORE) randomized trial
    Curnrnings, S.; Eckert, S.; Krueger, K.
  • Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study
    Fisher, B.; Costantino, J.; Wickerham, D.
  • Aromatase inhibitors and breast cancer
    Brodie, A.; Njar, V.
  • Aromatase inhibitors
    Miller, W.R.
  • Influence of letrozoie and anastrozole on total body arorealization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study
    Geisler, J.; Haynes, B.; Anker, G.
  • Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in post-menopausal women with advanced breast cancer: results of overview analysis of 2 phase III trials
    Buzdar, A.; Jonat, W.; Howell, A.
  • Anastrozoie vs megestrol acetate in the treatment of postmsnopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials
    Buzdar, A.; Jonat, W.; Howell, A.
  • Letrozoie, a new oral aromatase inhibitor for advanced breast cancer: doubie-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate
    Dombernowsky, P.; Smith, I.; Falkson, G.
  • Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate
    Buzdar, A.; Douma, J.; Davidson, N.
  • High activity and tolerability demonstrated for exemestane in postmenopausai women with metastatic breast cancer who had previously failed on tamoxifen treatment
    Kvinnsiand, S.; Anker, G.; Dirix, L.
  • Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial
    Lonning, P.; Bajetta, E.; Murray, R.
  • Third-line hormonal treatment with exemestane in postmenopausai patients with advanced breast cancer progressing on aminogiutethimide: a phase II multicentre multinational study: Exemestane Study Group
    Thurlimann, B.; Paridaens, R.; Serin, D.
  • Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausai women with advanced breast cancer: results of a phase III randomized double-blind trial
    Kaufmann, M.; Bajetta, E.; Dirix, L.
  • Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postraenopausal women: results of a North American multicenter randomized trial
    Nabhoitz, J.; Buzdar, A.; Pollak, M.
  • Anastrozoie versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the tamoxifen or Arimidex randomized group efficacy and tolerability study
    Bonneterre, J.; Thurlimann, B.; Robertson, J.
  • Superior efficacy of letrozoie versus tamoxifen as first-line therapy for postmenopausai women with advanced breast cancer: results of a phase III study of the International Letrozoie Breast Cancer Group
    Mouridsen, H.; Gershanovich, M.; Sun, Y.
  • Efficacy of and tolerance to exemestane versus tamoxifen in first line hormone therapy of postmenopausal metastatic breast cancer patients: a European Organisation for the Research and Treatment of cancer (EORTC Breast Group) Phase II trial with Pharmacia and Upjohn
    Dirix, L.; Piccart, M.; Lohrisch, C.
  • Anastrozole (Arimidex) versus tamoxifeu as first-line therapy for advanced breast cancer (ABC) in postmenopausal (PM) women — combined analysis from two identically designed multicenter trials [abstract 609D]
    Buzdar, A.; Nabhoitz, J.; Robertson, J.
  • Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC Randomised Trial
  • The influence of chemotherapy on survival after recurrence in breast cancer: a population based study of patients treated in the 1950s, 1960s, and 1970s
    Cold, S.; Jensen, N.; Brincker, H.
  • Palliative effect of chemotherapy: objective tumor response is associated with symptom improvement in patients with metastatic breast cancer
    Geels, P.; Eisenhauer, E.; Bezjak, A.
  • Metastatie breast cancer: higher versus low dose maintenance treatment when only a partial response or a no change status is obtained following doxorubicin induction treatment: an Eastern Cooperative Oncology Group study
    Falkson, G.; Gelman, R.; Glick, J.
  • Eastern Cooperative Oncology Group randomized trials of observation versus maintenance therapy for patients with metastatic breast cancer in complete remission following induction treatment
    Falkson, G.; Gelman, R.; Pandya, K.
  • Interrupted versus continuous chemotherapy in patients with metastatic breast cancer
    Muss, E.L.; Case, L.; Richards, F.
  • Current management of metastatic breast cancer
    Perez, E.
  • Epirubicin metabolism and pharmacokinetics after conventional- and high-dose intravenous administration: a cross-over study
    Camaggi, C.; Strocchi, E.; Carisi, P.
  • A prospective randomized phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil and with either doxorubicin or epirubicin
  • A prospective randomized trial comparing epirubicin monochemotherapy to two fluorouracil, cylophosphamide, and epirubicin regimens differing in epirubicin dose in advanced breast cancer patients
  • The bigger the better? Or what we know and what we still need to learn about anthracycline dose per course, dose density and cumulative dose in the treatment of breast cancer
    Biganzoli, L.; Piccart, M.
  • Second-line chemotherapy for metastatic breast cancer including quality of life issues
    Buzdar, A.; Hortobagyi, G.; Prye, D.
  • Docetaxei compared with sequential methotrexate and 5-fluorouracil in advanced breast cancer after anthracycline failure: a randomised phase III study with cross-over on progression by the Scandinavian Breast Cancer Group
    Sjostrom, J.; Biomqvist, C.; Mouridsen, H.
  • Prospective randomised trial of docetaxel vs mitomycin plus vinbiastine in patients with metastatic breast cancer progressing despite previous anthracyciine-containing chemotherapy
    Nabholtz, J.; Senn, J.; Beswoda, W.
  • Taxoiere vs 5-FU and Naveibine as second-line chemotherapy in patients wiith metastatic breast cancer
    Bonneterre, J.; Roche, H.; Monnier, A.
  • Prospective randomised phase III triai of docetaxel vs doxorubicin in patients with metastatic breast cancer
    Chan, S.; Friedrichs, K.; Noel, D.
  • Phase III trial of doxorubicin vs paclitaxel vs doxorabicin + paclitaxel as front-line chemotherapy for metastatic breast cancer; an intergroup trial [abstract]
    Sledge, G.W.; Neuberg, D.; Bernando, P.
  • Paclitaxel vs doxorabicin as first-line single agent chemotherapy for metastatic breast cancer; a European Organisation for Research and Treatment of Cancer randomised study with cross-over
    Paridaens, R.; Biganzoli, L.; Broiling, P.
  • Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer
    Bishop, J.; Dewar, J.; Toner, G.
  • Multicenter Phase II trial of weekly paclitaxel in women with metastatic breast cancer
    Perez, E.A.; Vogel, C.L.; Irwin, D.H.; Krishner, J.J.; Patel, R.
  • Docetaxel administered on a weekly basis for metastatic breast cancer
    Burstein, E.L.; Manola, J.; Younger, J.
  • Doxorabicin and paclitaxel versus fluorouracil, doxorabicin, and cyclophopsharnide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial
    Tassera J. Pienkowski, T.; Pluzanska, A.
  • Doxorubicin and paclitaxel versus doxorabicin and cyclophosphamide as first line chemtoherapy in metastatic breast cancer: the European Organisation for Research and Treatment of cancer 10961 multicenter phase III trial
    Biganzoli, L.; Cufer, T.; Braning, P.
  • Multicentric phase III study in first line treatment of advanced metastatic breast cancer (ABC): epirubicin/paclitaxel (ET) vs epirubicin/cyclophosphamide (EC) — a study of the AGO Breast Cancer Group
    Luck, E.L.; Thomssen, C.; Untch, M.
  • UKCCR trial of epirubicin and cyclophosphamide vs epirubicin and taxolin the first line treamtnet of women with metastatic breast cancer [abstract 84a]
    Carmichael, J.
  • Doccetexal and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast caner; results of a randomised, multicenter phase III triai
    Nabhoitz, J.-M.; Falkson, G.; Campos, D.
  • Final results of the phase III randomized trial comparing docetaxel (T), doxorabicin (A) and cyclophosphamide (C) to FAC as first line chemotherapy for patients with metastatic breast cancer [abstract 137]
    Mackey, J.; Paterson, A.; Dirix, L.
  • Phase II trial of doxorabicin and docetaxel plus granuiocyte colony-stimuitating factor in metastatic breast cancer: Eastern Cooperative Oncology Group Study E1196
    Sparano, J.; O’Neill, A.; Schaefer, P.
  • Phase II trial of doxorubicn and paclitaxel pius granuiocyte colony-stimulating factor in metastatic breast cancer: an Eastern Cooperative Oncology Group Study
    Sparano, J.; Hu, P.; Rao, R.
  • Paclitaxel by 3-hour infusion in combination with bolus doxorabicin in women with untreated metastatic breast cancer: high antiturnor efficacy and cardiac effects in a dose-finding and sequence-finding study
    Gianni, L.; Munzone, E.; Capri, G.
  • Phase III trial comparing TAC (docetaxel, doxorabicin, cyclophosphamide) with FAC (5-fluorouracil, doxorabicin, cyclophosphamide) in the adjuvant treatment of node positive breast cancer aptients: interim analysis of the BCIRG 001 study [abstract 141]
    Nabholtz, J.; Pienkowski, T.; Mackey, J.
  • Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer; preliminary results of a prospective randomised trial
    Buzdar, A.U.; Singletary, S.E.; Valero, V.
  • Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer
    Blum, J.; Jones, S.; Buzdar, A.
  • Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first line therapy for advanced/metastatic breast cancer
    O’Shaughnessy, J.; Blum, J.; Moiseyenko, V.
  • “Classical” CMF versus a 3-weekly intravenous CMF schedule in postmen op ausal patients with advanced breast cancer: an EORTC Breast Cancer Co-Operative Group Phase III Trial (10808)
    Engelsman, E.; Klijn, J.; Rubens, R.
  • Capecitabine (Xeloda) in patients with advanced breast cancer, previously treated with anthracycline s and taxanes: results of a large phase II study [abstract 247]
    Fumoleau, P.; Largillier, R.; Trillet-Lenoir, V.
  • Vinorelbine (naveibine) as a salvage treatment for advanced breast cancer
    Degardin, M.; Bonneterre, J.; Hecquet, B.
  • A review of the antitumour activity of vinorelbine in breast cancer
    Marty, M.; Extra, J.; Dieras, V.
  • Randomized comparison of vinorelbine and melphalan in anthracycline-refractory advanced breast cancer
    Jones, S.; Winer, E.; Vogel, C.
  • Activity of gemcitabine in metastatic breast cancer patients previously treated with anthracycline-containing regimens
    Spielmann, M.; Kalla, S.; Llombart-Cussac, A.
  • Second- and third-line treatent of metastatic breast cancer with gemcitabine
    Brodowicz, T.; Moslinger, R.; Herscovici, V.
  • Impact of selection process on response rate and long-term survival of potential high-dose chemotherapy candidates treated with standard-dose doxorubicin-containing chemotherapy in patients with metastatic breast cancer
    Rahman, Z.; Frye, D.; Buzdar, A.
  • High-dose chemotherapy with haemopoietic transplantation for metastatic breast cancer: results of the French protocol PEGASE 04 [abstract 161]
    Lotz, J.; Cure, H.; Janvier, M.
  • Conventional-dose chemotherapy compared with high-dose chemotherapy plus autoiogous haematopoetic stem cell transplant group
    Stadtmauer, E.; O’Neill, A.; Goldstein, L.
  • Conventional-dose chemotherapy compared with high-dose chemotherapy plus autoiogous stem-cell transplantation for metastatic breast cancer: 5-year update of the “Philadelphia Trial” [abstract 169]
    Stadtmauer, E.; O’Neill, A.; Goldstein, L.
  • Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer
    Paterson, A.; Powles, T.; Kanis, J.
  • Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomised controlled trial
    Conte, P.; Latrielle, J.; Mauriac, L.
  • Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases
    Hortobagyi, G.; Theriault, R.; Porter, L.
  • Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases
    Lipton, A.; Theriault, R.; Hortobagyi, G.
  • Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial-protocol 18 Aredia Breast Cancer Study Group
    Theriauit, R.; Lipton, A.; Hortobagyi, G.
  • The management of metastatic bone disease in the United Kingdom
  • American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer: American Society of Oncology Bisphosphonates Expert Panel
    Hillner, B.; Ingle, J.; Berenson, J.
  • Continual oral versus intravenous interval therapy with bisphosphonates in patients with breast cancer and bone metastases [abstract 488A]
    Diel, I.; Marschner, N.; Kindler, M.
  • Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene
    Slamon, D.J.; Clark, G.M.; Wong, S.G.
  • Phase II study of weekly intravenous recombinant humanized Anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer
    Baselga, J.; Tripathy, D.; Mendelsohn, 3.
  • Phase II study of receptor-enhanced chernosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment
    Pegram, M.D.; Lipton, A.; Hayes, D.F.
  • Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressiing metastatic breast cancer that has progressai after chemotherapy for metastatic disease
    Cobleigh, M.; Vogel, C.; Tripathy, D.
  • Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer
    Vogel, C.; Cobleigh, M.; Tripathy, D.
  • Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpreses HER2
    Slamon, J.; Leyland-Jones, B.; Shak, S.
  • Cardiac dysfunction in the trastuzumab clinical trials experience
    Seidman, A.; Hudis, C.; Pierri, M.
  • Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor
    Ciardiello, F.; Caputo, R.; Bianco, R.
  • Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by co-administration of ZD1839 (Iressa), an inhibtor of EGFR tyrosine kinase
    Sirotnak, F.; Zakowski, M.; Miller, V.
  • Role of MAP kinase in the enhanced cell proliferation of long-term estrogen deprived human breast cancer cells
    Jeng, M.; Yue, W.; Eischied, A.
  • Enhanced epidermal growth factor receptor signaling in MCF7 breast cancer cells after long-term culture in the presence of the pure antiestrogen LCI 182,780 (Faslodex)
    McClelland, R.; Barrow, D.; Madden, T.
  • Modulation of epidermal growth factor receptor in endocrine-resistant, oestrogen receptor-positive breast cancer
    Nicholson, R.; Hutcheson, I.; Harper, M.
  • The EGFR-selective tyrosine kinase inhibitor ZD1839 (Iressa) is an effective inhibitor of tarnoxifen-resistant breast cancer growth
    Gee, J.; Hutcheson, I.; Knowlden, J.
  • Aberrant function of the Ras signal transduction pathway in human breast cancer
    Clark, G.; Der, C.J.
  • Clinical activity with the farnesyl transferase inhibitor R115777 in patients with advanced breast cancer: relationship with tumour phenotype
    Johnston, S.; Hickish, T.; Ellis, P.